Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biomarin Pharmaceutical

55.27
-0.8400-1.50%
Post-market: 55.12-0.1500-0.27%19:48 EDT
Volume:2.54M
Turnover:141.24M
Market Cap:10.60B
PE:20.43
High:56.35
Open:56.08
Low:55.15
Close:56.11
Loading ...

Inozyme Pharma Announces Transaction Bonuses for Key Executives Following Merger Agreement

Reuters
·
02 Jun

S&P 500 Futures Rise In Premarket Trading; Trump Media & Tech, Stellantis Lead

Dow Jones
·
27 May

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

StockStory
·
27 May

Erin Burkhart, GVP and Chief Accounting Officer, Reports Disposal of BioMarin Pharmaceutical Inc. Common Shares

Reuters
·
21 May

Sector Update: Health Care Stocks Rise Friday Afternoon

MT Newswires Live
·
17 May

Leerink bullish on BioMarin following Inozyme deal, expects additional BD

TIPRANKS
·
17 May

Inozyme downgraded to Hold from Buy at Needham

TIPRANKS
·
17 May

Inozyme Shares More Than Double in Surge Toward BioMarin's Buyout Price

Dow Jones
·
16 May

Inozyme Pharma Shares up 178% on $270 Mln Buyout Deal With Biomarin

THOMSON REUTERS
·
16 May

BUZZ-U.S. STOCKS ON THE MOVE-Estee Lauder, Charter Communications, Vistra

Reuters
·
16 May

BUZZ-Inozyme Pharma rises over 175% on $270 million buyout deal with BioMarin

Reuters
·
16 May

BioMarin Pharmaceutical to Acquire Inozyme Pharma for $270 Million

MT Newswires Live
·
16 May

BioMarin’s acquisition of Inozyme to strengthen enzyme therapies portfolio

TIPRANKS
·
16 May

BRIEF-Biomarin To Acquire Inozyme Pharma

Reuters
·
16 May

BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M

TIPRANKS
·
16 May

BioMarin reaffirms previously provided full-year 2025 financial guidance

TIPRANKS
·
16 May

Inozyme Pharma Inc - Biomarin to Buy Inozyme for $270 Mln

THOMSON REUTERS
·
16 May

Biomarin Strengthens Enzyme Therapy Business With Acquisition of Inozyme Pharma

THOMSON REUTERS
·
16 May

BioMarin's Voxzogo Reduces Tibial Bowing in Young Children With Achondroplasia

MT Newswires Live
·
13 May

BioMarin Pharmaceutical Is Maintained at Buy by Goldman Sachs

Dow Jones
·
05 May